# Silymarin in COVID-19 Pneumonia

> **NCT04394208** · PHASE3 · UNKNOWN · sponsor: **Cairo University** · enrollment: 50 (estimated)

## Conditions studied

- COVID-19
- Viral Pneumonia Human Coronavirus

## Interventions

- **DRUG:** Silymarin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04394208
- **Lead sponsor:** Cairo University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-16
- **Primary completion:** 2021-01-30
- **Final completion:** 2021-02-28
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04394208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04394208, "Silymarin in COVID-19 Pneumonia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04394208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*